<qa>  What is the name of the DISORDERS that are characterized by CLOFARACLOFARABINE AND CYCLOPHOSPHAMIDE IN TREATING PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, OR MYELOPROLIFERATIVE DISORDERS: 